A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

Fiona Simpkins, Richard Drake, Pedro F. Escobar, Benjamin Nutter, Nabila Rasool, Peter G. Rose

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Objective. To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Methods. A phase II trial was conducted in patients with measurable disease. Paclitaxel (175 mg/m2/3 h), carboplatin (AUC 5) and bevacizumab (15 mg/kg) were administered q 21 days. Patients with a complete response after 6-8 cycles received maintenance therapy with bevacizumab 15 mg/kg q 21 days for 16 cycles. Based on GOG 177 which had a 6-month PFS rate of 59%, an increase in 6-month PFS to 72% with the treatment regimen was considered of clinical interest. Results. 15 patients were enrolled on protocol when accrual to the study was discontinued due to the initiation of a national randomized phase II trial. A total of 127 courses (median 8, range 1-20) of carboplatin, paclitaxel, and bevacizumab combination therapy were administered. One patient suffered a bowel perforation after her first course of therapy and was inevaluable for response. Fourteen of the 15 patients (93%, 95% CI: 82-100) were progression free at 6 months. The median follow-up was 36 months (7-58 +). The median PFS was 18 months (CI: 11-25). Five complete responses and 6 partial responses were seen for an overall response rate of 73% (CI: 45-91). The median overall survival was 58 months (CI: 48-68). Conclusions. The bevacizumab, paclitaxel, and carboplatin regimen is active and tolerable in advanced and recurrent EMCA. Its impact awaits results of the recently completed randomized phase II trial.

Original languageEnglish
Pages (from-to)240-245
Number of pages6
JournalGynecologic Oncology
Volume136
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Keywords

  • Advanced stage endometrial cancer
  • Bevacizumab
  • Chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Fingerprint Dive into the research topics of 'A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)'. Together they form a unique fingerprint.

  • Cite this